{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:28:40Z","timestamp":1761488920322,"version":"build-2065373602"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000245","name":"Michael Smith Foundation for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.vaccine.2011.12.093","type":"journal-article","created":{"date-parts":[[2012,5,16]],"date-time":"2012-05-16T13:37:49Z","timestamp":1337175469000},"page":"B57-B62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"S2","title":["Considerations for controlling invasive meningococcal disease in high income countries"],"prefix":"10.1016","volume":"30","author":[{"given":"Johan","family":"Holst","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanne","family":"N\u00f8kleby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie A.","family":"Bettinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"RR-16","key":"10.1016\/j.vaccine.2011.12.093_bib0005","first-page":"8","article-title":"Recommendations of the International Task Force for Disease Eradication (updated April 2008)","volume":"42","year":"1993","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0010","unstructured":"The World Bank Data: How we classify countries. http:\/\/data.worldbank.org\/about\/country-classifications; 2010 [cited 2011 September 3, 2011]."},{"key":"10.1016\/j.vaccine.2011.12.093_bib0425","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1586\/erv.11.159","article-title":"Epidemiology and prevention of meningococcal disease: a critical appraisal of vaccine policies","volume":"10","author":"S\u00e1fadi","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0020","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1586\/erv.09.18","article-title":"Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy","volume":"8","author":"Pace","year":"2009","journal-title":"Expert Rev Vaccines"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2011.12.093_bib0025","doi-asserted-by":"crossref","first-page":"B30","DOI":"10.1016\/j.vaccine.2009.05.003","article-title":"Quadrivalent meningococcal conjugate vaccines","volume":"27","author":"Pace","year":"2009","journal-title":"Vaccine"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2011.12.093_bib0030","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2009.04.071","article-title":"Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis","volume":"27","author":"Holst","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0035","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1473-3099(09)70324-X","article-title":"Serogroup B meningococcal vaccines\u2014an unfinished story","volume":"10","author":"Sadarangani","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0040","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","article-title":"Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing","volume":"287","author":"Pizza","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0045","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"Giuliani","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0050","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.vaccine.2009.12.026","article-title":"The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000\u20132007","volume":"28","author":"Bettinger","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0055","unstructured":"Emergence of antimicrobial-resistant serotype 19A Streptococcus pneumoniae\u2014Massachusetts, 2001\u20132006. MMWR Morb Mortal Wkly Rep 2007;56:1077\u201380."},{"key":"10.1016\/j.vaccine.2011.12.093_bib0060","unstructured":"Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction\u2014eight states, 1998\u20132005. MMWR Morb Mortal Wkly Rep 2008;57:144\u20138."},{"key":"10.1016\/j.vaccine.2011.12.093_bib0065","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/648593","article-title":"Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine","volume":"201","author":"Pilishvili","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0070","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1473-3099(04)01251-4","article-title":"Meningococcal polysaccharide\u2013protein conjugate vaccines","volume":"5","author":"Snape","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0075","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/INF.0b013e31819040e7","article-title":"The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada","volume":"28","author":"Bettinger","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0080","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1073\/pnas.94.1.271","article-title":"Capsule switching of Neisseria meningitidis","volume":"94","author":"Swartley","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0085","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1056\/NEJM200001203420319","article-title":"Rapid serogroup switching in Neisseria meningitidis","volume":"342","author":"Vogel","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0090","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1086\/651505","article-title":"Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era\u2014United States, 2000\u20132005","volume":"201","author":"Harrison","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0095","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/S0140-6736(00)03502-9","article-title":"Serogroup W135 meningococcal disease in Hajj pilgrims","volume":"356","author":"Taha","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0100","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0140-6736(02)07716-4","article-title":"W135 meningococcal disease in England and Wales associated with Hajj 2000 and 2001","volume":"359","author":"Hahne","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0105","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1086\/340414","article-title":"Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electophoretic type-37 complex","volume":"185","author":"Mayer","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0110","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1017\/S095026880999104X","article-title":"Emergence and disappearance of W135 meningococcal disease","volume":"138","author":"Wilder-Smith","year":"2010","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0115","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(99)00252-4","article-title":"Meningococcal conjugate vaccines: new opportunities and new challenges","volume":"354","author":"Maiden","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0120","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S1473-3099(06)70584-9","article-title":"No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales","volume":"6","author":"Trotter","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0125","doi-asserted-by":"crossref","first-page":"e8501","DOI":"10.1371\/journal.pone.0008501","article-title":"Influence of two vaccination campaigns on genetic diversity of invasive Neisseria meningitidis isolates in northern Spain (1997\u20132008)","volume":"4","author":"Vicente","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0130","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMra0906357","article-title":"Advances in the development of vaccines against Neisseria meningitidis","volume":"362","author":"Tan","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0135","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","article-title":"Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway","volume":"338","author":"Bjune","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0140","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/ije\/dyn228","article-title":"Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years","volume":"38","author":"Galloway","year":"2009","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0145","first-page":"6","article-title":"Cuban Meningococcal BC vaccine: experience and contribution from 20 years of application","volume":"9","author":"Sotolongo","year":"2007","journal-title":"MEDICC Rev"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0150","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.vaccine.2005.12.059","article-title":"Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks","volume":"25","author":"Taha","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0155","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1473-3099(11)70027-5","article-title":"From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak","volume":"11","author":"Caron","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0160","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1128\/jb.177.9.2475-2480.1995","article-title":"Variable expression of class 1 outer membrane protein in Neisseria meningitidis is caused by variation in the spacing between the \u221210 and \u221235 regions of the promoter","volume":"177","author":"van der Ende","year":"1995","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0165","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1128\/IAI.67.6.2928-2934.1999","article-title":"Deletion of porA by recombination between clusters of repetitive extragenic palindromic sequences in Neisseria meningitidis","volume":"67","author":"van der Ende","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0170","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jama.281.16.1520","article-title":"Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile","volume":"281","author":"Tappero","year":"1999","journal-title":"JAMA"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2011.12.093_bib0175","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1086\/648966","article-title":"Review of meningococcal group B vaccines","volume":"50","author":"Granoff","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0180","doi-asserted-by":"crossref","first-page":"8738","DOI":"10.1074\/jbc.M808831200","article-title":"Structural basis for the immunogenic properties of the meningococcal vaccine candidate LP2086","volume":"284","author":"Mascioni","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0185","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1016\/j.vaccine.2009.01.075","article-title":"Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide","volume":"27","author":"McNeil","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0190","series-title":"The 29th annual meeting of the European Society for Paediatric Infectious Diseases (ESPID), The Hague, The Netherlands, June 7\u201311, 2011","article-title":"Phase 2 randomised controlled clinical trial of safety and immunogenicity of a meningococcal b bivalent vaccine (rLP2086) in healthy adolescents","author":"Marshall","year":"2011"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0195","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1517\/14712598.2011.585965","article-title":"Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles","volume":"11","author":"Bai","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0200","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4049\/jimmunol.177.1.501","article-title":"The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance","volume":"177","author":"Madico","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0205","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1128\/IAI.72.7.4217-4223.2004","article-title":"NadA diversity and carriage in Neisseria meningitidis","volume":"72","author":"Comanducci","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0210","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1073\/pnas.0915162107","article-title":"Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans","volume":"107","author":"Serruto","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0215","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/IAI.72.4.2088-2100.2004","article-title":"Vaccine potential of the Neisseria meningitidis 2086 lipoprotein","volume":"72","author":"Fletcher","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0220","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1016\/j.vaccine.2010.06.083","article-title":"Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease","volume":"28","author":"Jiang","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0225","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.1073\/pnas.1013758107","article-title":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines","volume":"107","author":"Donnelly","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0230","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1128\/CVI.00027-10","article-title":"Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine","volume":"17","author":"Lucidarme","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0235","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1016\/j.vaccine.2011.04.092","article-title":"Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States","volume":"29","author":"Wang","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0240","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1016\/j.vaccine.2004.11.029","article-title":"Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine in toddlers and school children","volume":"23","author":"Findlow","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.epirev.a036242","article-title":"Whooping cough and whooping cough vaccine: the risks and benefits debate","volume":"4","author":"Miller","year":"1982","journal-title":"Epidemiol Rev"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0250","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/S0140-6736(77)90573-6","article-title":"Toxicity of pertussis vaccine","volume":"2","author":"Stewart","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0255","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(77)91028-5","article-title":"Vaccination against whooping-cough. Efficacy versus risks","volume":"1","author":"Stewart","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0260","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.1990.03440120101046","article-title":"\u2018Pertussis vaccine encephalopathy\u2019: it is time to recognize it as the myth that it is","volume":"263","author":"Cherry","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0265","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/archpedi.1990.02150250047029","article-title":"Comparison of acellular and whole-cell pertussis-component DTP vaccines. A multicenter double-blind study in 4- to 6-year-old children","volume":"144","author":"Morgan","year":"1990","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0270","first-page":"323","article-title":"Effect of aluminium hydroxide and meningococcal serogroup C capsular polysaccharide on the immunogenicity and reactogenicity of a group B Neisseria meningitidis outer membrane vesicle vaccine","volume":"92","author":"Rosenqvist","year":"1998","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0275","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1016\/j.vaccine.2007.01.023","article-title":"Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand","volume":"25","author":"Oster","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0280","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1016\/j.vaccine.2007.01.022","article-title":"Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease","volume":"25","author":"Nokleby","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0285","first-page":"95","article-title":"The Norwegian meningococcal group B outer membrane vesicle vaccine: side effects in phase II trials","volume":"14","author":"Nokleby","year":"1991","journal-title":"NIPH Ann"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0290","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","article-title":"MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain","volume":"23","author":"Oster","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0295","series-title":"The 29th annual meeting of the European Society for Paediatric Infectious Diseases (ESPID)","article-title":"Immunogenicity and tolerability of an investigational multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents","author":"Santolaya","year":"2011"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0300","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0305","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1097\/INF.0b013e3181f59f6d","article-title":"Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial","volume":"29","author":"Snape","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0310","doi-asserted-by":"crossref","first-page":"781","DOI":"10.4161\/hv.7.7.15997","article-title":"Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults","volume":"7","author":"Toneatto","year":"2011","journal-title":"Hum Vaccines"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0315","series-title":"The 29th annual meeting of the European Society for Paediatric Infectious Disease","article-title":"Reactogenicity and safety of multicomponent meningococcal serogroup B vaccine (4CMenB) administered with or without routine infant vaccinations in different schedules","author":"Beeretz","year":"2011"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0320","series-title":"17th international pathogenic Neisseria conference, Banff, Canada, September 11\u201316, 2010","article-title":"Tolerability of a three-dose schedule of an investigational, multicomponent, meningococcal sergroup B vaccine and routine infant vaccines in a lot consistency trial","author":"Esposito","year":"2010"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0325","doi-asserted-by":"crossref","first-page":"196","DOI":"10.4161\/hv.3.5.4458","article-title":"Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004\u20132006","volume":"3","author":"McNicholas","year":"2007","journal-title":"Hum Vaccines"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0330","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.vaccine.2007.12.001","article-title":"The risk of simple febrile seizures after immunisation with a new group B meningococcal vaccine, New Zealand","volume":"26","author":"Stehr-Green","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0335","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1016\/j.vaccine.2008.03.017","article-title":"The Intensive Vaccines Monitoring Programme (IVMP): an electronic system to monitor vaccine safety in New Zealand","volume":"26","author":"Tatley","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0340","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.2105\/AJPH.94.11.1926","article-title":"A global perspective on vaccine safety and public health: the Global Advisory Committee on Vaccine Safety","volume":"94","author":"Folb","year":"2004","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0345","first-page":"7","article-title":"Global Advisory Committee on Vaccine Safety, 12\u201313 December 2007","volume":"83","author":"Anonymous","year":"2008","journal-title":"WER"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0350","first-page":"1","article-title":"The risk of bronchiolitis hospitalisation following administration of a group B meningococcal vaccine in New Zealand","volume":"120","author":"Stehr-Green","year":"2007","journal-title":"N Z Med J"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0355","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/adc.2007.125195","article-title":"Henoch-Schonlein purpura and meningococcal B vaccination","volume":"94","author":"Sexton","year":"2009","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0360","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1586\/14760584.6.5.863","article-title":"Neurological adverse events of immunization: experience with an aluminum adjuvanted meningococcal B outer membrane vesicle vaccine","volume":"6","author":"N\u00f8kleby","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0365","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.vaccine.2008.10.043","article-title":"Vaccination as teenagers against meningococcal disease and the risk of the chronic fatigue syndrome","volume":"27","author":"Magnus","year":"2009","journal-title":"Vaccine"},{"issue":"Suppl 12","key":"10.1016\/j.vaccine.2011.12.093_bib0370","doi-asserted-by":"crossref","first-page":"S293","DOI":"10.1097\/01.inf.0000147645.53942.00","article-title":"The strategy to control New Zealand's epidemic of group B meningococcal disease","volume":"23","author":"O\u2019Hallahan","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0375","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1128\/CVI.00304-10","volume":"18","author":"Kimura","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0380","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1586\/14760584.1.2.161","article-title":"Methods of ensuring vaccine safety","volume":"1","author":"Ball","year":"2002","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0385","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/aje\/kwk045","article-title":"Risks of convulsion and aseptic meningitis following measles\u2013mumps\u2013rubella vaccination in the United Kingdom","volume":"165","author":"Miller","year":"2007","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0390","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3928\/0090-4481-20040901-11","article-title":"The role of the Vaccine Adverse Event Reporting system (VAERS) in monitoring vaccine safety","volume":"33","author":"Iskander","year":"2004","journal-title":"Pediatr Ann"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0395","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/pds.851","article-title":"The Brighton Collaboration: enhancing comparability of vaccine safety data","volume":"12","author":"Kohl","year":"2003","journal-title":"Pharmacoepidemiol Drug Safety"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0400","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1001\/jama.285.9.1183","article-title":"Time trends in autism and in MMR immunization coverage in California","volume":"285","author":"Dales","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0405","first-page":"195","article-title":"Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba","volume":"14","author":"Sierra","year":"1991","journal-title":"NIPH Ann"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0410","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/aje\/kwm147","article-title":"A prospective study of the effectiveness of the New Zealand meningococcal B vaccine","volume":"166","author":"Kelly","year":"2007","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0415","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1016\/j.vaccine.2011.06.120","article-title":"Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand","volume":"29","author":"Arnold","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.12.093_bib0420","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/bmj.327.7417.728","article-title":"How can doctors communicate information about risk more effectively","volume":"327","author":"Alaszewski","year":"2003","journal-title":"BMJ"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11020421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11020421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:18:47Z","timestamp":1759400327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X11020421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":84,"alternative-id":["S0264410X11020421"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.12.093","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Considerations for controlling invasive meningococcal disease in high income countries","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.12.093","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}